INDIAGLYCO

India Glycols has reported strong Q1 FY27 results

India Glycols has reported strong Q1 FY27 results with revenue up 9% to ₹1,130 crore and EBITDA up 13% to ₹170 crore. The National Company Law Tribunal (NCLT) has sanctioned its demerger plan, paving the way for three separate listed entities. 📊 Key Financial Highlights (Q1 FY27) Revenue: ₹1,130 crore (↑ 9% YoY) EBITDA: ₹170 crore (↑ 13% YoY) PAT (Profit After Tax): ↑ 32% YoY Finance Costs: Reduced to ₹25 crore (from ₹45 crore last year) due to debt reduction efforts 🔑 Strategic Updates Demerger Approved: NCLT sanctioned restructuring into three entities: IGL Spirits Limited – Potable spirits & bio-fuel Ennature Bio Pharma – Nutraceuticals, APIs, biopolymers India Glycols Limited – Bio-based chemicals, glycols, performance chemicals, gases Debt-Free Target: Company aims to be debt-free by FY28. Segment Growth: Spirits: Revenue ₹361 crore (↑ 5.3%), IMFL volumes surged 55% YoY. Bio-Fuel: Revenue ₹323 crore (↑ 7%), EBIT margin 8.4%. Chemicals: Revenue ₹362 crore (↑ 20.6%), performance chemicals grew 40%. ⚠️ Risks & Challenges Raw Material Volatility: Crude oil price fluctuations impacting margins. Freight Costs: Significant spikes affecting exports. Geopolitical Disruptions: Shipments to Middle East & US facing delays. Execution Risk: Smooth transition during demerger remains critical. 📌 Investor Takeaways Positive Outlook: Strong revenue & EBITDA growth, reduced debt, and demerger expected to unlock shareholder value. Valuation Potential: Focused entities may attract differentiated valuations. Watchpoints: Monitor raw material costs, freight rates, and execution of restructuring plan.